Werewolf Therapeutics Stock Forum

$Werewolf Therapeutics (HOWL.US)$
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three obje...

$Werewolf Therapeutics (HOWL.US)$
NEWS
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, ...

$Werewolf Therapeutics (HOWL.US)$ Werewolf Therapeutics Inc: Plans to Present Interim, First-in-Human Clinical Data From Ongoing Phase 1 Trial of Wtx-330 in Q2 of 2024

$Werewolf Therapeutics (HOWL.US)$ Upcoming Milestones! Most if not all data of some sort is to be released before end of Q2!
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Ph...

$Werewolf Therapeutics (HOWL.US)$ Werewolf Therapeutics Q3 2023 EPS $(0.23) Up From $(0.40) Revenue $5.897M Beats $1.592M Estimate

$Werewolf Therapeutics (HOWL.US)$ 👀werewolf in action now with massive buying volume today 🤣 lets hope its not spam in for few small postion